Your browser is no longer supported. Please, upgrade your browser.
NVUS Novus Therapeutics, Inc. weekly Stock Chart
NVUS [NASD]
Novus Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.69 Insider Own2.20% Shs Outstand10.04M Perf Week-3.27%
Market Cap65.36M Forward P/E- EPS next Y-1.47 Insider Trans0.00% Shs Float7.26M Perf Month3.33%
Income-14.50M PEG- EPS next Q-0.31 Inst Own51.60% Short Float0.25% Perf Quarter34.23%
Sales- P/S- EPS this Y81.40% Inst Trans-14.04% Short Ratio0.29 Perf Half Y71.56%
Book/sh3.14 P/B2.07 EPS next Y1.30% ROA-60.20% Target Price8.00 Perf Year22.14%
Cash/sh- P/C- EPS next 5Y- ROE-66.30% 52W Range3.12 - 8.61 Perf YTD60.34%
Dividend- P/FCF- EPS past 5Y6.80% ROI- 52W High-24.39% Beta0.50
Dividend %- Quick Ratio14.80 Sales past 5Y- Gross Margin- 52W Low108.65% ATR0.45
Employees8 Current Ratio14.80 Sales Q/Q- Oper. Margin- RSI (14)46.16 Volatility3.71% 7.02%
OptionableNo Debt/Eq0.00 EPS Q/Q15.30% Profit Margin- Rel Volume0.06 Prev Close6.51
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume61.44K Price6.51
Recom2.00 SMA20-3.28% SMA50-1.29% SMA20034.66% Volume3,938 Change0.00%
Feb-13-18Initiated Ascendiant Capital Markets Buy $7
Jun-19-18 07:30AM  Novus Therapeutics Receives FDA Guidance at Type C Meeting for OP-02 in the Treatment and Prevention of Otitis Media Business Wire +8.00%
May-11-18 09:15AM  Novus Therapeutics Reports First Quarter 2018 Financial Results Business Wire +11.98%
Apr-02-18 09:00AM  Novus Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update Business Wire -5.95%
Jan-05-18 07:20PM  Should You Invest In The Healthcare Stock Novus Therapeutics Inc (NASDAQ:NVUS)? Simply Wall St.
Nov-21-17 03:00PM  Novus Therapeutics to Present at the 29th Annual Piper Jaffray Healthcare Conference PR Newswire
12:49PM  Who Are The Largest Shareholders In Novus Therapeutics Inc (NVUS)? Simply Wall St.
Nov-08-17 04:52PM  Novus Therapeutics Reports Third Quarter 2017 Results PR Newswire
Nov-06-17 04:01PM  Novus Therapeutics Announces the Promotion of Dr. Catherine Turkel to President PR Newswire -6.56%
Oct-05-17 09:26AM  Whats The Outlook For Loss-Making Novus Therapeutics Inc (NVUS)? Simply Wall St.
Aug-09-17 06:08PM  Novus Therapeutics Reports Second Quarter 2017 Results PR Newswire
Jul-10-17 06:30AM  Novus Therapeutics Announces Change in Management PR Newswire
Jun-12-17 08:00AM  Novus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire
Novus Therapeutics, Inc., a pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is (OP-02), a surfactant-based combination drug product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology (OP-01) that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.